In recent years, the landscape surrounding the use of modafinil in Italy has undergone significant changes, reflecting broader trends in the pharmaceutical market, regulatory policies, and public perception of cognitive enhancers. Modafinil, a wakefulness-promoting agent primarily used to treat narcolepsy, sleep apnea, and shift work sleep disorder, has gained attention for its off-label use as
